Mark is responsible for developing and maintaining Osmosis’ quantitative research systems and models as well as conducting alpha-signal research. He is a highly experienced quantitative researcher and portfolio manager, having spent 14 years at GMO, four as a quant analyst and ten as a portfolio manager. During this time, he created and managed various funds including the GMO Quality and GMO Tactical Opportunities Funds. He was also Head of the Emerging Equities Quant Team for four years.
Mark gained his Master in Mathematics from Oxford University and is a CFA charter holder. Mark also serves as an external adviser to Kidney Research UK, the UK’s largest funder of kidney research.
IMPORTANT INFORMATION:
Global Investors (ex US and Australia). This document is issued in the UK by Osmosis Investment Management UK Limited (“Osmosis UK”). Osmosis UK is authorised and regulated by the Financial Conduct Authority “FCA” with FRN 765056. This document is a “financial promotion” within the scope of the rules of the FCA. In the United Kingdom, the issue or distribution of this document is being made only to and directed only at professional clients (as defined in the rules of the FCA) (“Professional Clients”). This document must not be acted or relied upon by persons who are not Professional Clients. Any investment or investment activity to which this document relates is available only to Professional Clients and will be engaged in only with Professional Clients.
US Investors.This document is issued by Osmosis Investment Management US LLC (“Osmosis US”). Osmosis US is regulated in the US by the SEC.
Australia Investors: This document is issued in Australia by Osmosis Investment Management (Australia) Pty Ltd (ABN 80 670 854 798, CAR No. 001305635) (“Osmosis AUS”) is a corporate authorised representative of Eminence Global Asset Management Pty Ltd which is the holder of an Australian Financial Services Licence (AFS Licence No. 305573).
Osmosis Investment Management NL B.V.: (“Osmosis NL”) is a Netherlands-based entity that has obtained a license from the Dutch Authority for the Financial Markets as an independent regulated alternative investment fund manager and provider of discretionary portfolio management services. Osmosis NL is an affiliate of Osmosis UK.
Osmosis UK, Osmosis US, and Osmosis AUS are wholly owned by Osmosis (Holdings) Limited (“OHL”) and collectively referred to throughout as “Osmosis”, and with Osmosis NL, are collectively referred to throughout as “Osmosis Group”.
© 2009 – 2024 OSMOSIS INVESTMENT MANAGEMENT
This site is designed for professional investors only.
You will now be redirected to our NL site. Fixed income solutions provided on the NL website are not available to US investors.
Please allow 48 business hours for your registration to be approved
Once a month, we curate the best of our insights for our subscribers. Sign up to our newsletter here.
